Skip to content

Author

J. Keenan

We have 2 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL.

Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients...

A. Major, Diana Abbott, Jordan Snyder et al. · 0 citations
Open access Sep 2026

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

This large collection of MBC cfDNA data is envisioned as an invaluable resource for the design and planning of future clinical trials, and cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials.

I. Leshchiner, A. Medford, J. Cha et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.